Enzyme therapy for lysosomal acid lipase deficiency in the mouse

Hong Du, Susan Schiavi, Mark Levine, Jaya Mishra, Martin Heur, Gregory A. Grabowski

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Lysosomal acid lipase (LAL) is the critical enzyme for the hydrolysis of the triglycerides (TG) and cholesteryl esters (CE) delivered to lysosomes. Its deficiency produces two human phenotypes, Wolman disease (WD) and cholesteryl ester storage disease (CESD). A targeted disruption of the LAL locus produced a null (lal-/-) mouse model that mimics human WD/CESD. The potential for enzyme therapy was tested using mannose terminated human LAL expressed in Pichia pastoris (phLAL), purified, and administered by tail vein injections to lal-/- mice. Mannose receptor (MR)-dependent uptake and lysosomal targeting of phLAL were evidenced ex vivo using competitive assays with MR-positive J774E cells, a murine monocyte/macrophage line, immunofluorescence and western blots. Following (bolus) IV injection, phLAL was detected in Kupffer cells, lung macrophages and intestinal macrophages in lal-/- mice. Two-month-old lal-/- mice received phLAL (1.5 U/dose) or saline injections once every 3 days for 30 days (10 doses). The treated lal-/- mice showed nearly complete resolution of hepatic yellow coloration; hepatic weight decreased by ∼36% compared to PBS-treated lal-/- mice. Histologic analyses of numerous tissues from phLAL-treated mice showed reductions in macrophage lipid storage. TG and cholesterol levels decreased by ∼50% in liver, 69% in spleen and 50% in small intestine. These studies provide feasibility for LAL enzyme therapy in human WD and CESD.

Original languageEnglish (US)
Pages (from-to)1639-1648
Number of pages10
JournalHuman molecular genetics
Volume10
Issue number16
StatePublished - Aug 1 2001

Fingerprint

Enzyme Therapy
Cholesterol Ester Storage Disease
Wolman Disease
Sterol Esterase
Macrophages
Injections
Liver
Triglycerides
Kupffer Cells
Pichia
Cholesterol Esters
Feasibility Studies
Mannose
Lysosomes
Lysosomal acid lipase deficiency
Small Intestine
Fluorescent Antibody Technique
Tail
Monocytes
Veins

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Du, H., Schiavi, S., Levine, M., Mishra, J., Heur, M., & Grabowski, G. A. (2001). Enzyme therapy for lysosomal acid lipase deficiency in the mouse. Human molecular genetics, 10(16), 1639-1648.

Enzyme therapy for lysosomal acid lipase deficiency in the mouse. / Du, Hong; Schiavi, Susan; Levine, Mark; Mishra, Jaya; Heur, Martin; Grabowski, Gregory A.

In: Human molecular genetics, Vol. 10, No. 16, 01.08.2001, p. 1639-1648.

Research output: Contribution to journalArticle

Du, H, Schiavi, S, Levine, M, Mishra, J, Heur, M & Grabowski, GA 2001, 'Enzyme therapy for lysosomal acid lipase deficiency in the mouse', Human molecular genetics, vol. 10, no. 16, pp. 1639-1648.
Du H, Schiavi S, Levine M, Mishra J, Heur M, Grabowski GA. Enzyme therapy for lysosomal acid lipase deficiency in the mouse. Human molecular genetics. 2001 Aug 1;10(16):1639-1648.
Du, Hong ; Schiavi, Susan ; Levine, Mark ; Mishra, Jaya ; Heur, Martin ; Grabowski, Gregory A. / Enzyme therapy for lysosomal acid lipase deficiency in the mouse. In: Human molecular genetics. 2001 ; Vol. 10, No. 16. pp. 1639-1648.
@article{79a7147bc62a43a28052a0d995699d85,
title = "Enzyme therapy for lysosomal acid lipase deficiency in the mouse",
abstract = "Lysosomal acid lipase (LAL) is the critical enzyme for the hydrolysis of the triglycerides (TG) and cholesteryl esters (CE) delivered to lysosomes. Its deficiency produces two human phenotypes, Wolman disease (WD) and cholesteryl ester storage disease (CESD). A targeted disruption of the LAL locus produced a null (lal-/-) mouse model that mimics human WD/CESD. The potential for enzyme therapy was tested using mannose terminated human LAL expressed in Pichia pastoris (phLAL), purified, and administered by tail vein injections to lal-/- mice. Mannose receptor (MR)-dependent uptake and lysosomal targeting of phLAL were evidenced ex vivo using competitive assays with MR-positive J774E cells, a murine monocyte/macrophage line, immunofluorescence and western blots. Following (bolus) IV injection, phLAL was detected in Kupffer cells, lung macrophages and intestinal macrophages in lal-/- mice. Two-month-old lal-/- mice received phLAL (1.5 U/dose) or saline injections once every 3 days for 30 days (10 doses). The treated lal-/- mice showed nearly complete resolution of hepatic yellow coloration; hepatic weight decreased by ∼36{\%} compared to PBS-treated lal-/- mice. Histologic analyses of numerous tissues from phLAL-treated mice showed reductions in macrophage lipid storage. TG and cholesterol levels decreased by ∼50{\%} in liver, 69{\%} in spleen and 50{\%} in small intestine. These studies provide feasibility for LAL enzyme therapy in human WD and CESD.",
author = "Hong Du and Susan Schiavi and Mark Levine and Jaya Mishra and Martin Heur and Grabowski, {Gregory A.}",
year = "2001",
month = "8",
day = "1",
language = "English (US)",
volume = "10",
pages = "1639--1648",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "16",

}

TY - JOUR

T1 - Enzyme therapy for lysosomal acid lipase deficiency in the mouse

AU - Du, Hong

AU - Schiavi, Susan

AU - Levine, Mark

AU - Mishra, Jaya

AU - Heur, Martin

AU - Grabowski, Gregory A.

PY - 2001/8/1

Y1 - 2001/8/1

N2 - Lysosomal acid lipase (LAL) is the critical enzyme for the hydrolysis of the triglycerides (TG) and cholesteryl esters (CE) delivered to lysosomes. Its deficiency produces two human phenotypes, Wolman disease (WD) and cholesteryl ester storage disease (CESD). A targeted disruption of the LAL locus produced a null (lal-/-) mouse model that mimics human WD/CESD. The potential for enzyme therapy was tested using mannose terminated human LAL expressed in Pichia pastoris (phLAL), purified, and administered by tail vein injections to lal-/- mice. Mannose receptor (MR)-dependent uptake and lysosomal targeting of phLAL were evidenced ex vivo using competitive assays with MR-positive J774E cells, a murine monocyte/macrophage line, immunofluorescence and western blots. Following (bolus) IV injection, phLAL was detected in Kupffer cells, lung macrophages and intestinal macrophages in lal-/- mice. Two-month-old lal-/- mice received phLAL (1.5 U/dose) or saline injections once every 3 days for 30 days (10 doses). The treated lal-/- mice showed nearly complete resolution of hepatic yellow coloration; hepatic weight decreased by ∼36% compared to PBS-treated lal-/- mice. Histologic analyses of numerous tissues from phLAL-treated mice showed reductions in macrophage lipid storage. TG and cholesterol levels decreased by ∼50% in liver, 69% in spleen and 50% in small intestine. These studies provide feasibility for LAL enzyme therapy in human WD and CESD.

AB - Lysosomal acid lipase (LAL) is the critical enzyme for the hydrolysis of the triglycerides (TG) and cholesteryl esters (CE) delivered to lysosomes. Its deficiency produces two human phenotypes, Wolman disease (WD) and cholesteryl ester storage disease (CESD). A targeted disruption of the LAL locus produced a null (lal-/-) mouse model that mimics human WD/CESD. The potential for enzyme therapy was tested using mannose terminated human LAL expressed in Pichia pastoris (phLAL), purified, and administered by tail vein injections to lal-/- mice. Mannose receptor (MR)-dependent uptake and lysosomal targeting of phLAL were evidenced ex vivo using competitive assays with MR-positive J774E cells, a murine monocyte/macrophage line, immunofluorescence and western blots. Following (bolus) IV injection, phLAL was detected in Kupffer cells, lung macrophages and intestinal macrophages in lal-/- mice. Two-month-old lal-/- mice received phLAL (1.5 U/dose) or saline injections once every 3 days for 30 days (10 doses). The treated lal-/- mice showed nearly complete resolution of hepatic yellow coloration; hepatic weight decreased by ∼36% compared to PBS-treated lal-/- mice. Histologic analyses of numerous tissues from phLAL-treated mice showed reductions in macrophage lipid storage. TG and cholesterol levels decreased by ∼50% in liver, 69% in spleen and 50% in small intestine. These studies provide feasibility for LAL enzyme therapy in human WD and CESD.

UR - http://www.scopus.com/inward/record.url?scp=0035423329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035423329&partnerID=8YFLogxK

M3 - Article

C2 - 11487567

AN - SCOPUS:0035423329

VL - 10

SP - 1639

EP - 1648

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 16

ER -